Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ADC THERAPEUTICS SA

(ADCT)
  Report
Delayed Nyse  -  04:00:02 2023-01-30 pm EST
4.920 USD   -2.57%
01/24Morgan Stanley Lowers Price Target on ADC Therapeutics to $5 From $7, Maintains Equalweight Rating
MT
01/11Transcript : ADC Therapeutics SA Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-11-2023 03:00 PM
CI
01/04IntoCell Announces the Signing of a Material Transfer Agreement with Option to License with ADC Therapeutics SA
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about ADC THERAPEUTICS SA
01/24Morgan Stanley Lowers Price Target on ADC Therapeutics to $5 From $7, Maintains Equalwe..
MT
01/11Transcript : ADC Therapeutics SA Presents at 41st Annual J.P. Morgan Healthca..
CI
01/04IntoCell Announces the Signing of a Material Transfer Agreement with Option to License ..
CI
01/04HC Wainwright Adjusts Price Target on ADC Therapeutics SA to $20 From $21, Maintains Bu..
MT
01/04ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
BU
01/03ADC Therapeutics Names Mohamed Zaki as Chief Medical Officer
MT
01/03ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer
BU
01/03ADC Therapeutics SA Announces Executive Changes
CI
2022ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA for the Tre..
AQ
2022Sector Update: Health Care Stocks Edge Higher Premarket Wednesday
MT
2022Sector Update: Health Care
MT
2022ADC Therapeutics Gets Conditional Marketing Authorization From European Commission for ..
MT
2022ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA« (loncastux..
BU
2022ADC Therapeutics SA Announces an Exclusive License Agreement with Mitsubishi Tanabe Pha..
CI
2022ADC Therapeutics SA and Swedish Orphan Biovitrum AB Announce the European Commission Ap..
CI
More most relevant news
All news about ADC THERAPEUTICS SA
01/24Morgan Stanley Lowers Price Target on ADC Therapeutics to $5 From $7, Maintains Equalwe..
MT
01/11Transcript : ADC Therapeutics SA Presents at 41st Annual J.P. Morgan Healthca..
CI
01/04IntoCell Announces the Signing of a Material Transfer Agreement with Option to License ..
CI
01/04Global markets live: Microsoft, Nvidia, Cisco, Salesforce, Rivian...
MS
01/04HC Wainwright Adjusts Price Target on ADC Therapeutics SA to $20 From $21, Maintains Bu..
MT
01/04ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
BU
01/03ADC Therapeutics Names Mohamed Zaki as Chief Medical Officer
MT
01/03ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer
BU
01/03ADC Therapeutics SA Announces Executive Changes
CI
2022ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA for the Tre..
AQ
More news
News in other languages on ADC THERAPEUTICS SA
01/04IntoCell annonce la signature d'un accord de transfert de matériel avec option de licen..
01/04ADC Therapeutics nimmt an der 41. jährlichen J.P. Morgan Healthcare Conference teil
01/04ADC Therapeutics participera à la 41e conférence annuelle J.P. Morgan Healthcare
01/04Bolsa de Madrid: Wall Street enfría un poco los ánimos
01/04Wall Street refroidit un peu l'ambiance
01/04Principales informations avant-Bourse
01/04En Direct des Marchés : Saint-Gobain, Sanofi, Arkema, GTT, Trigano..
01/04ADC Therapeutics ernennt Mohamed Zaki zum Chief Medical Officer
01/03ADC Therapeutics nomme Mohamed Zaki au poste de directeur médical
01/03ADC Therapeutics nomme Mohamed Zaki au poste de directeur médical en chef
More news
Analyst Recommendations on ADC THERAPEUTICS SA
01/24Morgan Stanley Lowers Price Target on ADC Therapeutics to $5 From $7, Maintains Equalwe..
MT
01/04HC Wainwright Adjusts Price Target on ADC Therapeutics SA to $20 From $21, Maintains Bu..
MT
2022Morgan Stanley Adjusts Price Target on ADC Therapeutics SA to $7 From $11, Maintains Eq..
MT
2022BofA Securities Downgrades ADC Therapeutics to Neutral From Buy, Adjusts Price Target t..
MT
2022RBC Cuts Price Target on ADC Therapeutics to $20 From $25, Notes Delay in Potential Cam..
MT
More recommendations
Press releases
01/04ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
BU
01/03ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer
BU
2022ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA for the Tre..
AQ
2022ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA« (loncastux..
BU
2022ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer
BU
More press releases
Upcoming event on ADC THERAPEUTICS SA